Project title: The platform for preclinical pharmacokinetics technology

Project leader: Su Zeng

Brief introduction: In order to cure the severe diseases of mankind, they combined the technology of molecular drug metabolism with high sensitivity analysis and thus established the drug metabolic activity screening and its evaluation model, which promoted the progress of preclinical research and evaluation technologies on drug metabolism.

 

Project title: The technology platform for novel drugs preclinical pharmacodynamic evaluations concerning anti-cancer, cardiovascular diseases and neuropsychiatric diseases.

Project leader: Bo Yang

Brief introduction: With the discoveries of novel targets and methods in the basic research of life sciences, this platform has established cellular, molecular and animal model that can closely simulate the pathogenesis of human disease, thus reflecting the drug’s efficacy with high accuracy and efficiency.

 

 

Project title:  The material basis of effective Chinese medicines and the key technologies for material resource’s bank research.

Project leader: Yiyu Cheng

Brief introduction: Develop world leading technologies in separation, purification and preparation of pharmacodynamic components in Chinese medicines. In order to maximally utilize the effective components and information of Chinese medicines, they have setup a world-class digital database for Chinese materia medica. It would provide technical support to speed up the development of new drugs.

 

 

 

Project title: New anti-Alzheimer's drug candidate BYYT-25 pre-clinical evaluation

Project leader: Yongzhou Hu

Brief introduction: After years of research, they found candidate compounds BYYT-25 with a novel structure and independent intellectual property rights. Based on SFDA’s 1.1 class technical requirements, they carried out a complete evaluation of its pharmacodynamics, safety and metabolism. These data on BYYT-25 laid foundations for further preclinical studies and clinical research.

 

 

Project title: The pre-clinical research of hypoxia-selective anticancer candidate compounds Q39 (Pharmaceutical chemicals Class 1)

Project leader: Qiaojun He

Brief introduction: Hypoxia in solid tumor is an important cause for its resistance to chemotherapy. They chose Q39 for its prominent anti-tumor activity in vitro and did a comprehensive analysis on its possible mechanisms, pharmacodynamics and toxicity. They discovered that Q39 alone have a strong anti-tumor activity and a wide safety range both in vivo and in vitro, making it a promising candidate. They have applied for China's invention patent, with independent intellectual property rights.

 

 

 

Project title: Novel topoisomerase II inhibitor ZL-006 pre-clinical evaluation

Project leader: Tao Liu
Brief introduction: Due to the multidrug resistance defects of etoposide, during its structural modifications that carried out earlier, they found a novel anti-tumor multidrug resistance compounds ZL-006 with independent intellectual property rights. On this basis, they intend to complete ZL-006 preclinical evaluation, including its pharmacodynamics and mechanisms.